Population Pharmacokinetics of Intravenous and Oral Acyclovir and Oral Valacyclovir in Pediatric Population To Optimize Dosing Regimens
Seef Abdalla, C. Briand, Mehdi Oualha, Miriam Friedman Ben‐David, Agathe Béranger, Sihem Benaboud, Jean‐Marc Tréluyer, Yi Zheng, Carmen Capito, Zeynep Demir, Frantz Foissac, Sarah Winter, Inès Gana, Sana Boujaafar, Naïm Bouazza, Déborah Hirt
Abstract
Acyclovir is an antiviral currently used for the prevention and treatment of herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections. This study aimed to characterize the pharmacokinetics (PK) of acyclovir and its oral prodrug valacyclovir to optimize dosing in children. Children receiving acyclovir or valacyclovir were included in this study. PK were described using nonlinear mixed-effect modeling. Dosing simulations were used to obtain trough concentrations above a 50% inhibitory concentration for HSV or VZV (0.